CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with ER+/HER2- localized breast cancer...
Phase 2
Berlin, Germany and 48 other locations
This study will compare DS 8201a to standard treatment.Participants must have HER2 breast cancer that has been treated before.Their ...
Phase 3
Berlin, Germany and 226 other locations
to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast...
Phase 3
Berlin, Germany and 114 other locations
A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer....
Phase 3
Berlin, Germany and 324 other locations
look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast...
Phase 3
Berlin, Germany and 147 other locations
This is a single-arm, open-label phase IV study of patients with advanced HR+/HER2- breast cancer who are treated first line with r...
Phase 4
Berlin, Germany and 51 other locations
PREcoopERA is a randomized (2:2:1), multicenter, open-label, three-arm (A, B, C), Window-of-Opportunity (WOO) trial to evaluate the activity and safe...
Phase 2
Berlin, Germany and 43 other locations
Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy a...
Phase 3
Berlin, Germany and 482 other locations
to standard endocrine therapy in patients with ER+/HER2 - early breast cancer with intermediate or high risk for disease recurrence...
Phase 3
Berlin, Germany and 692 other locations
growth factor receptor (HER)2-low, hormone receptor (HR) positive breast cancer patients whose disease has progressed on endocrine ...
Phase 3
Berlin, Germany and 293 other locations
Clinical trials
Research sites
Resources
Legal